Univeristy of North Carolina at Chapel Hill
Chapel Hill, North Carolina, 27514, United States
Location status: Recruiting
Location contact
Jennifer L Goralski, MD
CONTACT
Jennifer L Goralski, MD
PRINCIPAL_INVESTIGATOR
NCT Number: NCT06057714
The purpose of this study is to look at lung ventilation in people with cystic fibrosis over time (1 year) using magnetic resonance imaging (MRI) with an inhaled contrast gas, and compare these measures to lung function assessed by spirometry and multiple breath nitrogen washout. This study also looks at how these measures change in response to a pulmonary exacerbation and treatment (if applicable). Over the span of a year, participants would be asked to complete 3-5 visits to the University of North Carolina at Chapel Hill (UNC). with each lasting up to 4 hours. If participants do not have a pulmonary exacerbation during the year they would be asked to complete 3 visits (one at enrollment, a second roughly 2 weeks later, and the third approximately a year later). If participants do experience a CF pulmonary exacerbation they would complete 5 visits (Visit 1, Visit 2, two exacerbation visits with one before treatment and the other after, and Visit 3 at one year after Visit 1). Only one exacerbation per participant will be tracked. Participants are eligible for this study if they are 18 years old or older, have Cystic Fibrosis (CF) with mild lung disease (FEV1 >/= 60%), and can undergo an MRI. There are no known benefits for participating in this study.
Interested in participating?
Request Info18 year–99 year
All sexes
Observational
Chapel Hill, North Carolina, 27514, United States
Location status: Recruiting
Jennifer L Goralski, MD
CONTACT
Jennifer L Goralski, MD
PRINCIPAL_INVESTIGATOR
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Subjects presenting with any of the following will not be included in the trial:
Inhalation of a biologically inert contrast gas, perfluoropropane, combined with 19F-tuned MRI with image acquisition at breath-hold and during tidal breathing
Other names: Perfluoropropane (PFP)
Time frame: Day 1 to Day 14
VDP measured at Day 1 and Day 14, expressed as a percentage of total lung volume
Time frame: Day 1 to Day 365 (+/- 30 days)
Average of VDP measured at Day 1 and Day 14; subtracted from VDP at Day 365, expressed as a percentage of total lung volume
Time frame: Day 1 to Day 14
FLVlongtau2 measured at Day 1 and Day 14, expressed as a percentage of total lung volume
Time frame: Day 1 to Day 365 (+/- 30 days)
Average of FLVlongtau2 measured at Day 1 and Day 14; subtracted from FLVlongtau2 at Day 365, expressed as a percentage of total lung volume
Time frame: Day 1 to Day 365 (+/- 30 days)
Difference in VDP between baseline and exacerbation visit 1, expressed as a percentage of total lung volume.
Time frame: Day 1 to Day 365 (+/- 30 days)
Difference in FLVlongtau2 between baseline and exacerbation visit 1, expressed as a percentage of total lung volume.
Time frame: Day 1 to Day 365 (+/- 30 days)
Change in MRI severity score from baseline to Day 365.
Time frame: Day 1 to Day 14
Baseline is a mean of the VDP scores from Day 1 and Day 14 (expressed as percentage of lung).
Correlation of MRI scores with VDP and FLVlongtau2
Time frame: Day 1 to Day 14
Baseline is a mean of the FLVlongtau2 scores from Day 1 and Day 14 (expressed as percentage of lung).
Correlation of MRI scores with VDP and FLVlongtau2
Contact information is provided by the study sponsor or research team.
Jennifer L Goralski, MD
CONTACT
Margret Z Powell, BS
CONTACT
University of North Carolina, Chapel Hill
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02417740
Cardiovascular Abnormalities, Cardiovascular Diseases
Bethesda, Maryland, United States
View Trial DetailsNCT06654752
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Cystic Fibrosis
Birmingham, Alabama, United States
View Trial DetailsNCT00001532
Asthma, Bronchial Diseases
Bethesda, Maryland, United States
View Trial DetailsNCT07283770
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Cystic Fibrosis
Overland Park, Kansas, United States
View Trial Details